Venus Remedies, a Rs.460 crore pharma company, has suffered setback during the fourth quarter ended March 2013 and its net profit declined by 23.2 per cent to Rs.11.95 crore from Rs.15.56 crore in the corresponding period of last year. Its net sales improved by 10.2 per cent to Rs.125.03 crore from Rs.113.62 crore. With fall in profits, its EPS declined to Rs.11.34 from Rs.15.97 in the last period.

Venus Remedies launched world's first anti stress product Ezenus in easy to use herbal candy which is absolute safe, zero calorie and non addictive with clinically proven anti stress activity. It received market authorization in Mexico for Meropenem. It signed exclusive marketing rights deal for its novel antibiotic adjutant entity to South Africa's second largest pharmaceutical company – Adcock. The launched Elores – CSE 1034, a US patent protected product in India during the quarter.

The board of directors has recommended a dividend of 30% i.e. Rs. 3/- per share for the financial year ended March 31, 2013. The board also approved raising of funds by way of equity/convertible instruments in the company/its wholly owned subsidiary upto USD 30 million, on a preferential basis, subject to approval of the shareholders, statutory approvals, applicable laws, guidelines and regulations.

For the full year ended March 2013, Venus' net sales increased by 14.3 per cent to Rs.459 crore from Rs.402 crore in the previous year. Its net profit also moved up by 14.2 per cent to Rs.57.15 crore from Rs.50.03 crore and its EBDITA improved by 11.7 per cent to Rs.118 crore from Rs.106 crore. Annual EPS worked out to Rs. 54.21 as against Rs.51.35 in the previous year.